Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIEW1: Aflibercept for Neovascular AMD
NCT00509795Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2007
- Primary completion
- Sep 2010
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Started Aug 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00509795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509795.